Dyne Therapeutics
Advancing life-transforming therapies for serious muscle diseases
292 employees · est. 2018 · Waltham, United States
Entrada Therapeutics
Innovating to transform the treatment of serious diseases through establishing a new class of genetic medicines.
207 employees · est. 2016 · Boston, United States
Entrada Therapeutics is the older company (2018 vs 2016).
Side-by-Side Comparison
| Metric | Dyne Therapeutics | Entrada Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2018 | 2016 older |
| Headquarters | ||
| Headquarters | Waltham, United States | Boston, United States |
| Employees | ||
| Employees | 292 | 207 |
| Industry | ||
| Industry | Biotechnology, Health Care, Pharmaceutical | Biotechnology |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | IPO |
| Total Funding | ||
| Total Funding | Not tracked yet | $483.10M |
| Funding Rounds | ||
| Funding Rounds | 6 | 7 |
| Services | ||
| Services | Development of therapies for neuromuscular diseases, Clinical trials management, Research and development in genetic therapeutics | Development of intracellular therapeutics, Clinical trials, Research on undruggable targets, Development of disease-specific therapies |
| Target Customers | ||
| Target Customers | Patients with neuromuscular disorders, Healthcare professionals, Investors, Caregivers of patients with rare diseases | Patients with neuromuscular disorders, Families affected by Duchenne Muscular Dystrophy, Researchers and medical professionals, Biotechnology investors |
| Taxonomy | ||
| Taxonomy | Genetic Therapies, Neuromuscular Diseases, Muscle Targeting, Central Nervous System, Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1, Facioscapulohumeral Muscular Dystrophy, Pompe Disease, Nucleic Acid Delivery, Muscle Strength Restoration, Skeletal Muscle, Cardiac Muscle, Smooth Muscle, Precision Medicine, Therapeutic Development | Intracellular Therapeutics, Genetic Medicines, Neuromuscular Diseases, Inherited Retinal Diseases, Oligonucleotide Programs, Duchenne Muscular Dystrophy, Exon Skipping, Myotonic Dystrophy Type 1, Clinical-stage Biopharmaceutical, Boston Seaport Community, Proprietary Approaches, Versatile And Modular Development, Biopharma Innovation, Disease Transformation |
| Website | ||
| Website | dyne-tx.com | entradatx.com |
About Dyne Therapeutics
Dyne Therapeutics, founded in 2018 and headquartered in the United States, is a dynamic player in the Biotechnology, Health Care, and Pharmaceutical industries. With a slogan of "Advancing life-transforming therapies for serious muscle diseases," the company is committed to addressing significant un...
About Entrada Therapeutics
Entrada Therapeutics, founded in 2016, is a clinical-stage biopharmaceutical company based in Boston’s Seaport community. The company is committed to transforming therapeutic approaches for challenging diseases by focusing on intracellular targets previously deemed unreachable. With a mission encaps...
We will tell you when either one moves
BounceWatch watches Dyne Therapeutics and Entrada Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Dyne Therapeutics and Entrada Therapeutics — by email.
Frequently Asked Questions
Compare Dyne Therapeutics with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Dyne Therapeutics on 9 Jun 2026, and Entrada Therapeutics on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
